Indaptus Therapeutics, Inc. — Director's Dealing 2021

Aug 2, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Intec Parent Inc. (NTEC)
CIK: 0001857044
Period of Report: 2021-07-23

Reporting Person: Karah Hila (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$480.0	2026-05-22	Common Stock (281)		Direct
Stock Option (right to buy)	$355.2	2025-06-28	Common Stock (250)		Direct
Stock Option (right to buy)	$388.6	2026-06-28	Common Stock (250)		Direct
Stock Option (right to buy)	$24.6	2027-07-15	Common Stock (500)		Direct

Footnotes

F1: The stock options are fully vested and are exercisable.

F2: The options vest over a period of three years from June 28, 2019, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending June 28, 2022.

F3: The options vest over a period of three years from July 15, 2020, 33.3% on the first anniversary of such date and 8.33% every three months thereafter, ending July 15, 2023.